Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Novartis AG
  6. News
  7. Summary
    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novartis Expands Fill-and-Finish Deal with BioNTech for COVID-19 Jabs

10/21/2021 | 04:20am EST


ę MT Newswires 2021
All news about NOVARTIS AG
11/26Roche Shareholders Approve Deal to Buy Back Novartis' Stake in Swiss Drugmaker
MT
11/26Roche shareholders approve deal to buy Novartis's $20.7 billion stake
RE
11/26Roche Shareholders OK $21 Billion Repurchase Deal With Novartis
MT
11/26Roche shareholders approve deal to buy Novartis's $20.7 billion stake
RE
11/26NOVARTIS AG : Gets a Neutral rating from UBS
MD
11/24Novartis' Lung Cancer Therapy Receives South Korean Regulator's OK
MT
11/23EMEA MORNING BRIEFING : Stocks to Track Wall -2-
DJ
11/22Holmes defends beliefs in Theranos technology at her fraud trial
RE
11/22Alnylam Pharmaceuticals Upgraded to Outperform From Sector Perform by RBC After R&D Day..
MT
11/22MarketScreener's World Press Review - November 22, 2021
More news
Analyst Recommendations on NOVARTIS AG
More recommendations
Financials (USD)
Sales 2021 51 969 M - -
Net income 2021 12 189 M - -
Net Debt 2021 21 641 M - -
P/E ratio 2021 14,7x
Yield 2021 4,03%
Capitalization 181 B 181 B -
EV / Sales 2021 3,90x
EV / Sales 2022 3,66x
Nbr of Employees 108 000
Free-Float 85,7%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | NOVN | CH0012005267 | MarketScreener
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 80,94 $
Average target price 100,65 $
Spread / Average Target 24,3%
EPS Revisions
Managers and Directors
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Hans J÷rg Reinhardt Independent Non-Executive Chairman
John Tsai Chief Medical Officer
Klaus Moosmayer Chief Ethics Risk & Compliance Officer
Sector and Competitors
1st jan.Capi. (M$)
NOVARTIS AG-10.68%181 102
JOHNSON & JOHNSON1.82%419 109
ROCHE HOLDING AG16.05%336 162
PFIZER, INC.46.70%303 095
NOVO NORDISK A/S67.00%247 254
ELI LILLY AND COMPANY54.21%236 049